Skip to content

Research Program of TCM Intervention and Integrated Treatment on Diabetic Retinopathy

A Study on TCM -based comprehensive protocal of Prevention and Control in Diabetic Retinopathy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000139
Enrollment
Unknown
Registered
2008-08-17
Start date
2008-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Interventions

TCM Group:Study group(combined therapy with Intervention of TCM): Basic therapy & treatment for both Xu and Yu zheng. 1 Therapy for DM: To control blood glucose, blood pressure, and serum lipid throug
Control group:Control group Basic therapy & placebo 1Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education. 2placebo, Usage

Sponsors

Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with diabetes mellitus; 2. Diagnosed with non-proliferative diabetic retinopathy, including moderate and severe diabetic retinopathy, and corrected VA=45 letters(ETDRS), equivalent the decimal value of 0.16(20/125); 3. Diagnosed with the syndrome and signs of TCM; 4. HbA1C<=8.0%; 5. Ages ranged from 35 to 75 years; 6. Joined in the test voluntarily and signed the Informed consent by GCP regulation.

Exclusion criteria

Exclusion criteria: 1. Complicating severe vitreous hemorrhage, or requiring laser and vitreotomy treatment; 2. The patients who have been received the therapy of Retina laser photocoagulation; 3. The patients whose dioptric media is so turbid that hard to evaluate the fundus picture; 4. DMKA or other acute metabolic disturbance, or complicating severe acute infection within a month; 5. Having any allergic reaction to some drugs, food and pollen etc. or hypersensitiveness 6. Pregnant or breast feeding; 7. Combined with primarily severe diseases such as cardiovascular, hepatic, renal illness, hemopoietic system disease, and psychosis; 8. Combined with glaucoma, uveitis, ocular neuropathy and severe cataract etc.; 9. Participated in other clinical trial within 3 month.

Design outcomes

Primary

MeasureTime frame
incidence rate of proliferative diabetic retinopat;

Secondary

MeasureTime frame
OCT;Visual Function;FFA, FERG, OPs, PVEP;Change of Symptoms scores of TCM;Vision acuity, Funduscopy, Fundus photograph;Quality of life;

Countries

China

Contacts

Public ContactDuan junguo
duanjg@vip.sina.com+86 28 88890807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026